{"ticker": {"uuid": "61910527-1c5c-4eb2-89ea-15ea913b9982", "symbol": "ATRA", "name": "Atara Biotherapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBITDA forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "The article provides a financial overview of Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBITDA forward metric. It indicates that the market is closed with no trades showing, and provides links to various financial data and community too", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T17:11:53", "published_display": "13 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "This article provides financial information for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBIT forward metric. It details that the market is currently closed, with no trades, and offers various financial resources and market data for t", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:51", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "The article provides a financial snippet for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, indicating no current trades and directing use", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T21:08:56", "published_display": "12 Jul 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) on behalf of investors who purchased shares before May 20, 2024, and continue to hold them. The investigation focuses on whether Atara and its officers engaged in corpo", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atara-biotherapeutics-inc.-atra-investigation-bronstein-gewirtz-1182492", "source_name": "ACCESS Newswire", "published_at": "2026-07-12T11:00:00", "published_display": "12 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ATRA) Movement", "summary": "This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA), highlighting its near-term weak sentiment and a mid-channel oscillation pattern. It identifies a significant short setup with an exceptional risk-reward ratio and provides three distinct AI-generated trading strateg", "url": "https://news.stocktradersdaily.com/news_release/11/Avoiding_Lag:_Real-Time_Signals_in_ATRA_Movement_071226024201_1783838521.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T02:40:27", "published_display": "12 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Atara Biotherapeutics Inc. (ATRA) stock, showing its current price of $9.94, up $0.30 (3.06%). It also notes that there are currently no analyst ratings or earnings information available for the company. The page features trading guid", "url": "https://timothysykes.com/quote/ATRA/", "source_name": "timothysykes.com", "published_at": "2026-07-09T21:17:28", "published_display": "09 Jul 2026 21:17", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) for alleged corporate wrongdoing. The firm encourages investors who purchased Atara securities before May 20, 2024, and continue to hold them, to join the investigation", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1182491", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics(ATRA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gJBVV95cUxQZy1CS1BWOHQ3LTNpTWdyOUR6dTJxRnBQdFQwcWh0bHpZbTFhNlpORy1CcGNFWTM3QzJDTGNuOGU5RDNSdy1qOGZCVHY4bjRpTk9WanpkRVliSTctajE4OVBHRUFCbFlOSnFCVTBVSnpOcGZIRWl6Z1JOZWViXzlxSGhfSHBlQ2hVQUxyd0RDV3p1TVZtc3ZOMzZmRkVWbExtV2dQeERiWnlHYS1uNk1SNzJsNjFKWjNsZFFVRzBTRkpVazU1QjQzMXhHQWt6MDVzQlAxMjZIbXJyT3dPUzAzOXVaU1hDT3Y5ZEtIbldZZ2xYSTF5VHBlZ3l2ZkM4TUZFQmg3azMwclpmcU5MYTNSQWpfand1LV85RThCb1BCUlg4dlo4N3ZNajY0aEtuTU5vdmt4ekVqcTFiWUcteDVaQldBd3dJTkR2WDd0LTRrWTdzekVXRnRMWkNGWlJpUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T18:19:26+00:00", "published_display": "08 Jul 2026 18:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Atara securities before May 20, 2024, and still hol", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182490", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T11:40:59", "published_display": "08 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3", "summary": "Atara Biotherapeutics' interim CFO, Kevin G. Sarney, has filed an initial Form 3, which is a statement of beneficial ownership. This filing identifies him as an officer of the company but reports no transactions or holdings. Form 3 acts as an initial inventory sheet for insiders'", "url": "https://www.stocktitan.net/sec-filings/ATRA/form-3-atara-biotherapeutics-inc-initial-statement-of-beneficial-owne-79525957142b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:10:10", "published_display": "06 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) securities who bought shares prior to May 20, 2024, and still hold them. The investigation aims to determine if Atara and its officers or dire", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-atara-biotherapeut-1182489", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T23:41:15", "published_display": "05 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA - Atara Biotherapeutics Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview and key performance indicators for Atara Biotherapeutics Inc (ATRA). It includes market capitalization, income, sales, various financial ratios, insider and institutional ownership, and stock performance metrics. The data is bas", "url": "https://finviz.com/stock?t=ATRA&p=d&ty=lf&b=1&r=m6&page=36", "source_name": "Finviz", "published_at": "2026-07-03T10:39:30", "published_display": "03 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into alleged corporate wrongdoing by Atara Biotherapeutics, Inc. (ATRA) and its officers/directors. Investors who purchased Atara securities before May 20, 2024, and still hold them, are encouraged to contact the f", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1182488", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on behalf of investors who suffered losses between May 20, 2024, and January 9, 2026. The lawsuit alleges that Atara made false and misleading statements rega", "url": "https://natlawreview.com/press-releases/atra-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-atara-0", "source_name": "The National Law Review", "published_at": "2026-07-01T08:40:31", "published_display": "01 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ATRA Response", "summary": "Quantitative Research Desk provides an analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA), identifying strong near- and mid-term sentiment but a weak long-term outlook. The report highlights resistance testing and an exceptional risk-reward short setup. It also outlines specif", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_ATRA_Response_070126013401_1782884041.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T01:34:00", "published_display": "01 Jul 2026 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) due to alleged misstatements regarding manufacturing issues and the integrity of the ALLELE study, making FDA approval unlikely. Investors who purchased Atara", "url": "https://natlawreview.com/press-releases/atra-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-atara-1", "source_name": "The National Law Review", "published_at": "2026-06-30T16:39:55", "published_display": "30 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing. The firm is encouraging stockholders who purchased Atara securities prior to May 20, 2024, and still hold them, to come forward and ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1182486", "source_name": "ACCESS Newswire", "published_at": "2026-06-29T08:40:32", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell Microcap Value Benchmark Index", "summary": "Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has been removed from the Russell Microcap Value Benchmark Index. This news follows a similar announcement on June 28, 2026, regarding its removal from the Russell 3000E Value Benchmark. The company, an allogeneic T-cell immunotherapy f", "url": "https://www.marketscreener.com/news/atara-biotherapeutics-inc-nasdaqgs-atra-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdcd88ef421", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:40:31", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20)", "summary": "This article provides an overview of Atara Biotherapeutics Inc (AT20) stock on the GETTEX exchange, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, market capitaliz", "url": "https://www.tradingview.com/symbols/GETTEX-AT20/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-28T15:41:14", "published_display": "28 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO", "summary": "Atara Biotherapeutics announced leadership changes in its finance organization, with Chief Accounting Officer Yanina Grant-Huerta's employment ending on July 17, 2026. The company appointed Kevin G. Sarney of Charles River CFO, Inc. as interim Chief Financial Officer, Principal F", "url": "https://www.stocktitan.net/sec-filings/ATRA/8-k-atara-biotherapeutics-inc-reports-material-event-e28aa2c0a2b7.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:45", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA)", "summary": "This article provides an overview of Atara Biotherapeutics, Inc. (ATRA) stock, including its current price, historical performance, and analyst forecasts. It also details financial metrics such as earnings per share, revenue, net income, and market capitalization, along with upco", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Atara Biotherapeutics, Inc. (ATRA) stock, including current price, analyst price targets, and historical performance. It also details the company's financials such as recent earnings, revenue, market capitalization, and upcoming earnings dates", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:50", "published_display": "25 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis", "summary": "Atara Biotherapeutics Inc (ATRA) currently holds a valuation score of 7.36, ranking 235 out of 387 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -7.24, showing significant deviation from its recent high and low P/E values. Key valuation metrics like P/", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T18:39:50", "published_display": "24 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities. The investigation concerns whether Atara and its officers or directors engaged in corporate wrongdoing, specifically for investor", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-atara-biotherapeut-1170746", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T22:09:43", "published_display": "21 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Atara Biotherapeutics Inc (ATRA) has an earnings forecast score of 7.50, ranking 286th in its industry. Analysts have an average price target of $17.00 for ATRA, with forecasts ranging from $16.00 to $18.00, suggesting a potential upside of over 42%. Based on 4 analysts, the cons", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:17", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Institutional Confidence", "summary": "Atara Biotherapeutics Inc (ATRA) has an institutional shareholding score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 28.53% quarter-over-quarter to 43.48%. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:17", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for alleged corporate wrongdoing. Shareholders who purchased Atara securities before May 20, 2024, are encouraged to contact the firm to assist with the investig", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1170745", "source_name": "ACCESS Newswire", "published_at": "2026-06-18T00:39:59", "published_display": "18 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Atara Biotherapeutics Inc (ATRA) and its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:37", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Atara Biotherapeutics Inc (ATRA)'s dividend history and stock split events. It states that the company has not distributed dividends in the past five years and details several recent merger-related stock splits with a 25-to-1 ratio, all dated ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:37", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcWFEakI5dXhfQjhwNzBxRWt1dmNKYThYVnFYV2VEX19CSHYwbkZiYXNVTkR6T2dPbjhWV0RaVlBiQk1XQTlkWTF0dE45YXhSbTV0WElIS3lyQ1VqWXUtYUtzVjBTZnJVb3FXaFVUbjQybEliNTEwcjczNnV4MjJwLW1KNTVnOUh2Mk5KZ1BZdWQzdHM4REM2Q1JJbG9yRVdiNXlFT2tUOG5YNlVhUDZZVGdCU1hXVko5MEhF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Announces Changes to Its Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUG9hM2JZSG5fX2M4VGNRZVRZMFB4TlhpSXQwN2UzSnZnU09ua044VTBJQVdvdG5VaVM4b01qMm84MF9aTGtmU0pNMENfdkYwZnZENlVBTERFUmctVDROTG1TNnhKdnlUSTNBQUdTcUJULVI2QXNubnpiOE13WHlHaE4wXzJGVTZXNTJVQ3h4aEtjX2Y4ZjF6eGI5SVQwZ1hWMEh4cHZDbGFHdW1fZklFcWlnQnczb0lLMmt5cVVnOA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxOcktNbXZjclltWkV2T1ZXOHZOQ3o1YVVfTENLdHBHMlVwSWpwQk9EbHZqNHNaNnNuUUpQMUF0VlVLb3VuUGNxYmJ6R3BGYjVxRjkzdEp2bExaYkxHem9YMDlGNi1TSmJsaTg4TUVoZDlKdXV4eWZ6cUJ3Y05aaWtKTllvaVpwdWlzdEdYQldZaHdDc2VWTUpRRXVHWE5CbWl0LVYwX1hMVTlEc2E3aW1WSHdkZUtPZnc4Z0ZDM2JFWEZtRG9samVYOU1MRHVvRnl2eWlCa2d2S0lEZTFhc2lGNnNHdzBFMTRQRDBNQkpWd2IxdW0zdUg5a2tqbzIzckxhcjF6eHAyeS1vU1g1UkhrQTA0emNZZmtsVm1PQmxUSWxTOHZWeW1ZTF9aM1FvZ1hudFFrV0tqbnZYYlQzdFFwbmNxTnU2TTl0NWFJSFJUaFg?oc=5", "source_name": "Business Wire", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOTHZLclJTaGFoQndmUjZCNklnSlVsV1VKcTdGOXVMSk95SDU2Nmd5ZWpsTHkzTmNiZld0cm5fbEdCaVZ5bUlLdzNWZ0steXFJX2ZrNGtqWXJDa0REQTlla3o5V0E2VlJfMkRBU1RtME5PV002MkZ4WUItUmRJZmlEaFlQMF9lOUNKdGZXM05yZ1I1b0tSa25nM0t6V2EzcXlHckZPZ1dDbllzallBSjViQnZIeFVEbFpFN3J4WE1zQVVBQWNCQ1Fya3hXU051c1JSakpzX25QaWNBdEU2VTJtWko3Y0paLVE0bm5kcmdKTU51MGROZmZ0MnZSaGg4ZWJucWs0OA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Bounces Back with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE05dDYxbjZmX1hwY196UTNhUlh0SEtMOTN4TzJPcjhhZzdYcE03UHEySldHNTBhU3Vzc1lyTlozeXRwT0tmQ2tWU3NMMDVpV05zSzRrTlBSTkp0Rm4zOVhTRW9oOEt3LWtzdHVuemZDVG1LTkJVUFE?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atara Biotherapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/atara-biotherapeutics-q1-earnings-snapshot-204026260.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:40:26+00:00", "published_display": "12 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZG9ZcVdWSFZLb0M2am1PSnhBQk5qTWtJbEdtVG5qaFNRbG8zd1ZiaURncjlubEZpZmFpVk5DVjNEWEZhbHJNM1AySjlYblpoRDMzblo1eXA4M3FrTDJWTFdJaWlIRU94Q2kzWElTMkZJLW8wNWJqRTNzWjBkWlNhMFQ2MUtfTzYxbUgwZDhLRXRuQkRfMno1bGY3VFhRYzVyN2M2bVdvbzhPdzE2ZTNDUjByX20xeXVDZnFF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atara Biotherapeutics stock surges on FDA resubmission guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNODU0akthOGVtcVZEdW5SRngyQmNaaHp3LS1EYlE5WWRXT2hBamVuaUdUUUNjcFFXcHYyMzJQM3ByTmp1NVRfakNhVWx6M2hKY1BSbnNULTNDZlJuS2FUOXBhRERVX25pMjBHOFN5U3J4M2R3dURCcjdJQmRSUW4yWmVKZ1lJcUdUTmV2ZWZhY3AzSlZ6bjU4SGlQdlFrcWZlVVV6N3lybUhTTnJ4VXByVHdwcE5xOHR5bTYtamNlZXlTMlU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Resubmission Path for Tab-cel Keeps Atara\u2019s (ATRA) Regulatory Timeline Alive", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQNVBLTlpCYnphOTRjb2h5NUViU2d4WkQ3eGNTVGNvaTJmWldyYVZhbWRmcTVnYzcxLXdCRHIwNldkcUYyVU1Bd0hkZDE0LW1VR0h6cU5UUWRHeUx3X0tvUkhHb3VQTmhNT2lxUWdZc0NXR2xBVG9LRVgyZGROQTBCZGJMYzZNdEVURThtcGhtdS1oV0Z3YnZVQXNRU2dJcVU?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says single-arm study could back Atara's tab-cel refiling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSHBYbzFNUnZYUDY0em5jSm9jbkRNNUx1UWVCeFAyUUNjN29iM3lrLVh4bXBORDFKOS0tRVp0RjdPa285UlpBRjk4UW1nREFvdUxyYkJFZFBiMjhnd1lXdWdjMXBjdUpjMVhWVmJ5ZzVZRGR3UHZaV0FEcVd2Yzg2NW91cVlMNXRXOVlaaDluSHRod1ZiTDd0RjlTdEtXNDdydnUzOHVEdDhyQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics,", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxPQ1hhcVJuQjFTdkN1SVRzMEZVeDdpT0RoaTFXUjJPQmFIajBpancxQ1JpOWdMcWhjc3ozUWVhczAwXzIta3ZfNWU5TmlNZHVQOXVIdDNwa0Z4MFBoUnlGTDJ5NVY5Y1RqQlRPNkt5T1lDMDlDdjAwbnZBa3hvZUpQRU9RaW1QQ2p5N2d6OXpFTG5Qc2w3RkZkTmtMeF9UTThPT1pEYUNCYWxuU1duYW5EUVg4VzctQ182bVNJSWFUYzUtUndLQzBKb2h3WFo0akNfbjAyWXZCWEpaQWhWSnBGSllCbU1fRmIwbU1QYlVLcXlncjRtU0lmdmZKbkY4ajlNR0txZ1ZfbHVFV1JCNXpYNHRCbzhJVzQzSzFUS19DWWduVnpmWGdzNjdKWXZ5bS1RVlZRc1dHdjBKQ0hF?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM2tnZFpEUzlsUWhrSnBsalFpWHAxZzVLSmFOSE5tN3ZtcjZITjVxcGg2aTNLS2pNVFBDRG9wdm1DdkFlbmQ5S0JIUHdGdlNIb0ljYVFOWFdmdHFpUjBrNXE5QnRraVViQ05jbHJiMWZPLXJGUU56SnNZT3BOcE0xYm42d2JmSVZxMEJic1BiV1R4aXkxdTFhUGd2S0pDaXY2QW91aW1HT293TXBwX2c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQYmdqamktRmhJX1UzRUlVc2JIQTNYZnhOTl9VdzFCSDZYQVhWcUowUWtPTnZBaGtBMVliUWZwbGtqdXJtbnlCQ2lTWXJVY1JOdE52TjV4QTdJWlg3U2NHQjVDXzhQQ0dmdGp4UHkzU3d1N1pmbUw0MFBhYTU5dkhkampkd2lXT21FbVlYOEpzWDdyRlFnMVUwZC1BVHB4QldjaldFb0d6ekNlcktlU3lrcVdJdmV6QnRyY3JuYlhTWjV5Ulg0ZmRGS0dMakJwNUVNaUNsc2FyUTdfWktZbVBEUzFnOG8yNHk0Qk9vY0hVY3p2dw?oc=5", "source_name": "Business Wire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara presses FDA meeting on T-cell therapy for ultra-rare PTLD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZXFQZE1IelBjRzhoaVV1aGtvM1U2UjFPd2lNaUlGSXNGc2g3NVBDanU1QmQ2cy1aODFfVWVRQW1wWWw0aE81Y1hVdWs4VGZFMTFMUXI2RmI2c0ZQRWpWaUlMUXlTdjF5RS1lcnB3UzZSeFE2T1JRdTBMaVc4MFhYaFpFRHR4VmJZOEhwQ2FsbldlNEhSLVVEWmZSdUNUdzA5VnE1YV9NNzRXUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQlZGeUdzVGNYak1YNG42dDktUU1NbjdfOVpEU3JPM3JHNGNmSjJ4b0dKbklyU3FaS2hrbU55UzJ0VXhENUtFeEZJNnZWeU5sZ18xTVVud3UxWEJrZ3hXR05TRURDdW1PZEhjcnktOVB2VndvTVlWNjJoSmdjaUxsZUhGZTZ4UnU1RTh0X0ExaVhDWk9JdUViRGpTZmtsR0h1S25mNkpKTWk?oc=5", "source_name": "Business Wire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Once a Ventura County biotech heavyweight, Atara fights for its life", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNRXVwV2tpcEFsZTJkMVRraG1EUTFFT1FFSTVMV1kyYUkwZnYyWEhPVTZIR21PSGtqNVRnbXFSLVowZURLZF8zWDFjaExvMjdjbFowWndJaGg4V3hOSVdfNVF3TGxxNVRRU2xadUxBUmplN0pRbHU4dmh4Qk9ZSC1adzdTM2dJaDRXWG1vbGZhQ1VpOU42MlhZVmFzOVRDdlZOREt6VXpqVzNpdkZE?oc=5", "source_name": "Ventura County Star", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Again Rejects Atara", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBjc0R4T1l3bmpHZ2NaRmwwdjZrUi1aS0ZTc2RFVFRFZnRfXy0yd3Q3bjl2Sk1KQnVWYzZkYm52WUltc184Vk1sdGVrTmRnZGI5aWFEWnE4N0VVZGdtdE96Nng1QWJ1ZGZoX0pxUWRuTFE?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics stock plunges after FDA rejects cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNdDEzVGFnaDBMSmxqYUNGUWJrcjRhWk5aVlZDNkhsZlhzeERnTmdRWDJ6YjBJYzZUTk5nd0pGRG5lZWxEMUZOa1EwSUQ5MklpVFV5Tl8tV3ZaOU1jWmJjMC1iRmxFT01MTmx2Q01UeHBYVDg0aDJQd1hnSkNVSEswS2VpYnZ4VXRqTjdBZkhDWjUzVUlKeGotMGxjT095TFF1dDNOU3FiRFJuTXNnZUpsYzBGR0N0dXNtY2dkWjdEby1xV0w2anBXalpB?oc=5", "source_name": "Investing.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOZ0VWME5lRTdBVEdzX2RWSkZKV2lKSUFwNHVBYlozbkNRUVo4Wk5DbG1hVjBsTWJmYWhqUEptRGthSFJCXzhmbFljM3hJcE5DT1BKUDc2eUxGd0ZtRm1iMnlGeTk5SmVZTXc0YWxhYnRHSmlYTjk4dHM3WHRKVmFpdFhGanRjT01ycnc5Sk1iWnhvbjBTY2RQdEEwaXBUMzhFbmRKd2tjeWRrSExCbTZwWEtzckl6Vi1mazZNOXFySXFyalFndDhBRzN3Z1drWkNDWW1j?oc=5", "source_name": "GuruFocus", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO\u2122 (tabelecleucel)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdDdCelRHM1A3X0ZkZExVSlUzV1RFaVozM3NkQVRzN0xacGd0VXY2S2RCbUhJbE83SWxtOUh6c1N3bXFfRWZwZ1pWNElkdTRQbEl0bUR6eEc1YjA3dHprVkNFSGtidDRucmpuNTVzSkl4bWM2VUFBa3Nnd0Q4WVdOdENrbDlMd1VlMTJIMnpfQlAwN0xTZ2E4ZFNtZDRUMldzVU16NFBKMGJ6d0ltbjFmNnVsX2VJNGJXdlBNaVpocXpOUXNVT1o2UUFEYmthbXFOTHY4ekhTNnlMOEE?oc=5", "source_name": "Business Wire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Atara's therapy for rare blood cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNYWp5VDE5NTZzRmxwZ1ZYb3RwUXhaRVNnZV9vejRyUHhiRzFZaU8tX214NUtIQlo3TDFZd0VXUUJJcXgtbWJWQjJuVmFXd2FvX0IxNzI3YkpIZzhXTzA4MlF0Tkk0TDIyc1VNZ2hEcFRQYWhLdVFqQTdoZE84X3ZxSERsclFkbFhCSngtaVFZM0lob0hQSHJjYi12UXJHUGJFd0hRaUJJWm45M290WW9vT0R6ZzI1QTlUR1B1SE0xUlV2T255Mkt3?oc=5", "source_name": "Reuters", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNTJiSm55YW40ejlsRm5Cd3I2SDVvZWhqYWt6VE5MVHNEUTZaQ1dQVy1RbXFuM0I3cC14Z2pFVlgwNENHSUJxRlVPT3RMWGRIOE9LMU5NaU5nUTl1ZzN2Y3pKMHVvTmx0cUtZdU91a1RlUHhvakdVNnNibWNVQUJrcmhQV1o1aTZzM2s0S0ctX2o2a2RKVmlJWlZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-30T08:00:00+00:00", "published_display": "30 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "The article provides a financial overview of Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBITDA forward metric. It indicates that the market is closed with no trades showing, and provides links to various financial data and community too", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T17:11:53", "published_display": "13 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "This article provides financial information for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBIT forward metric. It details that the market is currently closed, with no trades, and offers various financial resources and market data for t", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:51", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atara Biotherapeutics Inc \u2013 MUN:AT20", "summary": "The article provides a financial snippet for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, indicating no current trades and directing use", "url": "https://www.tradingview.com/symbols/MUN-AT20/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T21:08:56", "published_display": "12 Jul 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) on behalf of investors who purchased shares before May 20, 2024, and continue to hold them. The investigation focuses on whether Atara and its officers engaged in corpo", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atara-biotherapeutics-inc.-atra-investigation-bronstein-gewirtz-1182492", "source_name": "ACCESS Newswire", "published_at": "2026-07-12T11:00:00", "published_display": "12 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ATRA) Movement", "summary": "This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA), highlighting its near-term weak sentiment and a mid-channel oscillation pattern. It identifies a significant short setup with an exceptional risk-reward ratio and provides three distinct AI-generated trading strateg", "url": "https://news.stocktradersdaily.com/news_release/11/Avoiding_Lag:_Real-Time_Signals_in_ATRA_Movement_071226024201_1783838521.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T02:40:27", "published_display": "12 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Atara Biotherapeutics Inc. (ATRA) stock, showing its current price of $9.94, up $0.30 (3.06%). It also notes that there are currently no analyst ratings or earnings information available for the company. The page features trading guid", "url": "https://timothysykes.com/quote/ATRA/", "source_name": "timothysykes.com", "published_at": "2026-07-09T21:17:28", "published_display": "09 Jul 2026 21:17", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) for alleged corporate wrongdoing. The firm encourages investors who purchased Atara securities before May 20, 2024, and continue to hold them, to join the investigation", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1182491", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics(ATRA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gJBVV95cUxQZy1CS1BWOHQ3LTNpTWdyOUR6dTJxRnBQdFQwcWh0bHpZbTFhNlpORy1CcGNFWTM3QzJDTGNuOGU5RDNSdy1qOGZCVHY4bjRpTk9WanpkRVliSTctajE4OVBHRUFCbFlOSnFCVTBVSnpOcGZIRWl6Z1JOZWViXzlxSGhfSHBlQ2hVQUxyd0RDV3p1TVZtc3ZOMzZmRkVWbExtV2dQeERiWnlHYS1uNk1SNzJsNjFKWjNsZFFVRzBTRkpVazU1QjQzMXhHQWt6MDVzQlAxMjZIbXJyT3dPUzAzOXVaU1hDT3Y5ZEtIbldZZ2xYSTF5VHBlZ3l2ZkM4TUZFQmg3azMwclpmcU5MYTNSQWpfand1LV85RThCb1BCUlg4dlo4N3ZNajY0aEtuTU5vdmt4ekVqcTFiWUcteDVaQldBd3dJTkR2WDd0LTRrWTdzekVXRnRMWkNGWlJpUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T18:19:26+00:00", "published_display": "08 Jul 2026 18:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Atara securities before May 20, 2024, and still hol", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1182490", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T11:40:59", "published_display": "08 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3", "summary": "Atara Biotherapeutics' interim CFO, Kevin G. Sarney, has filed an initial Form 3, which is a statement of beneficial ownership. This filing identifies him as an officer of the company but reports no transactions or holdings. Form 3 acts as an initial inventory sheet for insiders'", "url": "https://www.stocktitan.net/sec-filings/ATRA/form-3-atara-biotherapeutics-inc-initial-statement-of-beneficial-owne-79525957142b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:10:10", "published_display": "06 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) securities who bought shares prior to May 20, 2024, and still hold them. The investigation aims to determine if Atara and its officers or dire", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-atara-biotherapeut-1182489", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T23:41:15", "published_display": "05 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA - Atara Biotherapeutics Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview and key performance indicators for Atara Biotherapeutics Inc (ATRA). It includes market capitalization, income, sales, various financial ratios, insider and institutional ownership, and stock performance metrics. The data is bas", "url": "https://finviz.com/stock?t=ATRA&p=d&ty=lf&b=1&r=m6&page=36", "source_name": "Finviz", "published_at": "2026-07-03T10:39:30", "published_display": "03 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into alleged corporate wrongdoing by Atara Biotherapeutics, Inc. (ATRA) and its officers/directors. Investors who purchased Atara securities before May 20, 2024, and still hold them, are encouraged to contact the f", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1182488", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on behalf of investors who suffered losses between May 20, 2024, and January 9, 2026. The lawsuit alleges that Atara made false and misleading statements rega", "url": "https://natlawreview.com/press-releases/atra-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-atara-0", "source_name": "The National Law Review", "published_at": "2026-07-01T08:40:31", "published_display": "01 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ATRA Response", "summary": "Quantitative Research Desk provides an analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA), identifying strong near- and mid-term sentiment but a weak long-term outlook. The report highlights resistance testing and an exceptional risk-reward short setup. It also outlines specif", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_ATRA_Response_070126013401_1782884041.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T01:34:00", "published_display": "01 Jul 2026 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) due to alleged misstatements regarding manufacturing issues and the integrity of the ALLELE study, making FDA approval unlikely. Investors who purchased Atara", "url": "https://natlawreview.com/press-releases/atra-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-atara-1", "source_name": "The National Law Review", "published_at": "2026-06-30T16:39:55", "published_display": "30 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing. The firm is encouraging stockholders who purchased Atara securities prior to May 20, 2024, and still hold them, to come forward and ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1182486", "source_name": "ACCESS Newswire", "published_at": "2026-06-29T08:40:32", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell Microcap Value Benchmark Index", "summary": "Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has been removed from the Russell Microcap Value Benchmark Index. This news follows a similar announcement on June 28, 2026, regarding its removal from the Russell 3000E Value Benchmark. The company, an allogeneic T-cell immunotherapy f", "url": "https://www.marketscreener.com/news/atara-biotherapeutics-inc-nasdaqgs-atra-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdcd88ef421", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:40:31", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20)", "summary": "This article provides an overview of Atara Biotherapeutics Inc (AT20) stock on the GETTEX exchange, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, market capitaliz", "url": "https://www.tradingview.com/symbols/GETTEX-AT20/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-28T15:41:14", "published_display": "28 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO", "summary": "Atara Biotherapeutics announced leadership changes in its finance organization, with Chief Accounting Officer Yanina Grant-Huerta's employment ending on July 17, 2026. The company appointed Kevin G. Sarney of Charles River CFO, Inc. as interim Chief Financial Officer, Principal F", "url": "https://www.stocktitan.net/sec-filings/ATRA/8-k-atara-biotherapeutics-inc-reports-material-event-e28aa2c0a2b7.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:45", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA)", "summary": "This article provides an overview of Atara Biotherapeutics, Inc. (ATRA) stock, including its current price, historical performance, and analyst forecasts. It also details financial metrics such as earnings per share, revenue, net income, and market capitalization, along with upco", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Atara Biotherapeutics, Inc. (ATRA) stock, including current price, analyst price targets, and historical performance. It also details the company's financials such as recent earnings, revenue, market capitalization, and upcoming earnings dates", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:50", "published_display": "25 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis", "summary": "Atara Biotherapeutics Inc (ATRA) currently holds a valuation score of 7.36, ranking 235 out of 387 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -7.24, showing significant deviation from its recent high and low P/E values. Key valuation metrics like P/", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T18:39:50", "published_display": "24 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities. The investigation concerns whether Atara and its officers or directors engaged in corporate wrongdoing, specifically for investor", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-atara-biotherapeut-1170746", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T22:09:43", "published_display": "21 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Atara Biotherapeutics Inc (ATRA) has an earnings forecast score of 7.50, ranking 286th in its industry. Analysts have an average price target of $17.00 for ATRA, with forecasts ranging from $16.00 to $18.00, suggesting a potential upside of over 42%. Based on 4 analysts, the cons", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:17", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Institutional Confidence", "summary": "Atara Biotherapeutics Inc (ATRA) has an institutional shareholding score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 28.53% quarter-over-quarter to 43.48%. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:17", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for alleged corporate wrongdoing. Shareholders who purchased Atara securities before May 20, 2024, are encouraged to contact the firm to assist with the investig", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-atara-biothe-1170745", "source_name": "ACCESS Newswire", "published_at": "2026-06-18T00:39:59", "published_display": "18 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Atara Biotherapeutics Inc (ATRA) and its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:37", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Atara Biotherapeutics Inc (ATRA)'s dividend history and stock split events. It states that the company has not distributed dividends in the past five years and details several recent merger-related stock splits with a 25-to-1 ratio, all dated ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atra/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:37", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcWFEakI5dXhfQjhwNzBxRWt1dmNKYThYVnFYV2VEX19CSHYwbkZiYXNVTkR6T2dPbjhWV0RaVlBiQk1XQTlkWTF0dE45YXhSbTV0WElIS3lyQ1VqWXUtYUtzVjBTZnJVb3FXaFVUbjQybEliNTEwcjczNnV4MjJwLW1KNTVnOUh2Mk5KZ1BZdWQzdHM4REM2Q1JJbG9yRVdiNXlFT2tUOG5YNlVhUDZZVGdCU1hXVko5MEhF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Announces Changes to Its Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUG9hM2JZSG5fX2M4VGNRZVRZMFB4TlhpSXQwN2UzSnZnU09ua044VTBJQVdvdG5VaVM4b01qMm84MF9aTGtmU0pNMENfdkYwZnZENlVBTERFUmctVDROTG1TNnhKdnlUSTNBQUdTcUJULVI2QXNubnpiOE13WHlHaE4wXzJGVTZXNTJVQ3h4aEtjX2Y4ZjF6eGI5SVQwZ1hWMEh4cHZDbGFHdW1fZklFcWlnQnczb0lLMmt5cVVnOA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxOcktNbXZjclltWkV2T1ZXOHZOQ3o1YVVfTENLdHBHMlVwSWpwQk9EbHZqNHNaNnNuUUpQMUF0VlVLb3VuUGNxYmJ6R3BGYjVxRjkzdEp2bExaYkxHem9YMDlGNi1TSmJsaTg4TUVoZDlKdXV4eWZ6cUJ3Y05aaWtKTllvaVpwdWlzdEdYQldZaHdDc2VWTUpRRXVHWE5CbWl0LVYwX1hMVTlEc2E3aW1WSHdkZUtPZnc4Z0ZDM2JFWEZtRG9samVYOU1MRHVvRnl2eWlCa2d2S0lEZTFhc2lGNnNHdzBFMTRQRDBNQkpWd2IxdW0zdUg5a2tqbzIzckxhcjF6eHAyeS1vU1g1UkhrQTA0emNZZmtsVm1PQmxUSWxTOHZWeW1ZTF9aM1FvZ1hudFFrV0tqbnZYYlQzdFFwbmNxTnU2TTl0NWFJSFJUaFg?oc=5", "source_name": "Business Wire", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOTHZLclJTaGFoQndmUjZCNklnSlVsV1VKcTdGOXVMSk95SDU2Nmd5ZWpsTHkzTmNiZld0cm5fbEdCaVZ5bUlLdzNWZ0steXFJX2ZrNGtqWXJDa0REQTlla3o5V0E2VlJfMkRBU1RtME5PV002MkZ4WUItUmRJZmlEaFlQMF9lOUNKdGZXM05yZ1I1b0tSa25nM0t6V2EzcXlHckZPZ1dDbllzallBSjViQnZIeFVEbFpFN3J4WE1zQVVBQWNCQ1Fya3hXU051c1JSakpzX25QaWNBdEU2VTJtWko3Y0paLVE0bm5kcmdKTU51MGROZmZ0MnZSaGg4ZWJucWs0OA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Bounces Back with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE05dDYxbjZmX1hwY196UTNhUlh0SEtMOTN4TzJPcjhhZzdYcE03UHEySldHNTBhU3Vzc1lyTlozeXRwT0tmQ2tWU3NMMDVpV05zSzRrTlBSTkp0Rm4zOVhTRW9oOEt3LWtzdHVuemZDVG1LTkJVUFE?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/atara-biotherapeutics-q1-earnings-snapshot-204026260.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:40:26+00:00", "published_display": "12 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZG9ZcVdWSFZLb0M2am1PSnhBQk5qTWtJbEdtVG5qaFNRbG8zd1ZiaURncjlubEZpZmFpVk5DVjNEWEZhbHJNM1AySjlYblpoRDMzblo1eXA4M3FrTDJWTFdJaWlIRU94Q2kzWElTMkZJLW8wNWJqRTNzWjBkWlNhMFQ2MUtfTzYxbUgwZDhLRXRuQkRfMno1bGY3VFhRYzVyN2M2bVdvbzhPdzE2ZTNDUjByX20xeXVDZnFF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics stock surges on FDA resubmission guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNODU0akthOGVtcVZEdW5SRngyQmNaaHp3LS1EYlE5WWRXT2hBamVuaUdUUUNjcFFXcHYyMzJQM3ByTmp1NVRfakNhVWx6M2hKY1BSbnNULTNDZlJuS2FUOXBhRERVX25pMjBHOFN5U3J4M2R3dURCcjdJQmRSUW4yWmVKZ1lJcUdUTmV2ZWZhY3AzSlZ6bjU4SGlQdlFrcWZlVVV6N3lybUhTTnJ4VXByVHdwcE5xOHR5bTYtamNlZXlTMlU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Resubmission Path for Tab-cel Keeps Atara\u2019s (ATRA) Regulatory Timeline Alive", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQNVBLTlpCYnphOTRjb2h5NUViU2d4WkQ3eGNTVGNvaTJmWldyYVZhbWRmcTVnYzcxLXdCRHIwNldkcUYyVU1Bd0hkZDE0LW1VR0h6cU5UUWRHeUx3X0tvUkhHb3VQTmhNT2lxUWdZc0NXR2xBVG9LRVgyZGROQTBCZGJMYzZNdEVURThtcGhtdS1oV0Z3YnZVQXNRU2dJcVU?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says single-arm study could back Atara's tab-cel refiling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSHBYbzFNUnZYUDY0em5jSm9jbkRNNUx1UWVCeFAyUUNjN29iM3lrLVh4bXBORDFKOS0tRVp0RjdPa285UlpBRjk4UW1nREFvdUxyYkJFZFBiMjhnd1lXdWdjMXBjdUpjMVhWVmJ5ZzVZRGR3UHZaV0FEcVd2Yzg2NW91cVlMNXRXOVlaaDluSHRod1ZiTDd0RjlTdEtXNDdydnUzOHVEdDhyQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics,", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxPQ1hhcVJuQjFTdkN1SVRzMEZVeDdpT0RoaTFXUjJPQmFIajBpancxQ1JpOWdMcWhjc3ozUWVhczAwXzIta3ZfNWU5TmlNZHVQOXVIdDNwa0Z4MFBoUnlGTDJ5NVY5Y1RqQlRPNkt5T1lDMDlDdjAwbnZBa3hvZUpQRU9RaW1QQ2p5N2d6OXpFTG5Qc2w3RkZkTmtMeF9UTThPT1pEYUNCYWxuU1duYW5EUVg4VzctQ182bVNJSWFUYzUtUndLQzBKb2h3WFo0akNfbjAyWXZCWEpaQWhWSnBGSllCbU1fRmIwbU1QYlVLcXlncjRtU0lmdmZKbkY4ajlNR0txZ1ZfbHVFV1JCNXpYNHRCbzhJVzQzSzFUS19DWWduVnpmWGdzNjdKWXZ5bS1RVlZRc1dHdjBKQ0hF?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM2tnZFpEUzlsUWhrSnBsalFpWHAxZzVLSmFOSE5tN3ZtcjZITjVxcGg2aTNLS2pNVFBDRG9wdm1DdkFlbmQ5S0JIUHdGdlNIb0ljYVFOWFdmdHFpUjBrNXE5QnRraVViQ05jbHJiMWZPLXJGUU56SnNZT3BOcE0xYm42d2JmSVZxMEJic1BiV1R4aXkxdTFhUGd2S0pDaXY2QW91aW1HT293TXBwX2c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQYmdqamktRmhJX1UzRUlVc2JIQTNYZnhOTl9VdzFCSDZYQVhWcUowUWtPTnZBaGtBMVliUWZwbGtqdXJtbnlCQ2lTWXJVY1JOdE52TjV4QTdJWlg3U2NHQjVDXzhQQ0dmdGp4UHkzU3d1N1pmbUw0MFBhYTU5dkhkampkd2lXT21FbVlYOEpzWDdyRlFnMVUwZC1BVHB4QldjaldFb0d6ekNlcktlU3lrcVdJdmV6QnRyY3JuYlhTWjV5Ulg0ZmRGS0dMakJwNUVNaUNsc2FyUTdfWktZbVBEUzFnOG8yNHk0Qk9vY0hVY3p2dw?oc=5", "source_name": "Business Wire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara presses FDA meeting on T-cell therapy for ultra-rare PTLD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZXFQZE1IelBjRzhoaVV1aGtvM1U2UjFPd2lNaUlGSXNGc2g3NVBDanU1QmQ2cy1aODFfVWVRQW1wWWw0aE81Y1hVdWs4VGZFMTFMUXI2RmI2c0ZQRWpWaUlMUXlTdjF5RS1lcnB3UzZSeFE2T1JRdTBMaVc4MFhYaFpFRHR4VmJZOEhwQ2FsbldlNEhSLVVEWmZSdUNUdzA5VnE1YV9NNzRXUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQlZGeUdzVGNYak1YNG42dDktUU1NbjdfOVpEU3JPM3JHNGNmSjJ4b0dKbklyU3FaS2hrbU55UzJ0VXhENUtFeEZJNnZWeU5sZ18xTVVud3UxWEJrZ3hXR05TRURDdW1PZEhjcnktOVB2VndvTVlWNjJoSmdjaUxsZUhGZTZ4UnU1RTh0X0ExaVhDWk9JdUViRGpTZmtsR0h1S25mNkpKTWk?oc=5", "source_name": "Business Wire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Once a Ventura County biotech heavyweight, Atara fights for its life", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNRXVwV2tpcEFsZTJkMVRraG1EUTFFT1FFSTVMV1kyYUkwZnYyWEhPVTZIR21PSGtqNVRnbXFSLVowZURLZF8zWDFjaExvMjdjbFowWndJaGg4V3hOSVdfNVF3TGxxNVRRU2xadUxBUmplN0pRbHU4dmh4Qk9ZSC1adzdTM2dJaDRXWG1vbGZhQ1VpOU42MlhZVmFzOVRDdlZOREt6VXpqVzNpdkZE?oc=5", "source_name": "Ventura County Star", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Again Rejects Atara", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBjc0R4T1l3bmpHZ2NaRmwwdjZrUi1aS0ZTc2RFVFRFZnRfXy0yd3Q3bjl2Sk1KQnVWYzZkYm52WUltc184Vk1sdGVrTmRnZGI5aWFEWnE4N0VVZGdtdE96Nng1QWJ1ZGZoX0pxUWRuTFE?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics stock plunges after FDA rejects cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNdDEzVGFnaDBMSmxqYUNGUWJrcjRhWk5aVlZDNkhsZlhzeERnTmdRWDJ6YjBJYzZUTk5nd0pGRG5lZWxEMUZOa1EwSUQ5MklpVFV5Tl8tV3ZaOU1jWmJjMC1iRmxFT01MTmx2Q01UeHBYVDg0aDJQd1hnSkNVSEswS2VpYnZ4VXRqTjdBZkhDWjUzVUlKeGotMGxjT095TFF1dDNOU3FiRFJuTXNnZUpsYzBGR0N0dXNtY2dkWjdEby1xV0w2anBXalpB?oc=5", "source_name": "Investing.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOZ0VWME5lRTdBVEdzX2RWSkZKV2lKSUFwNHVBYlozbkNRUVo4Wk5DbG1hVjBsTWJmYWhqUEptRGthSFJCXzhmbFljM3hJcE5DT1BKUDc2eUxGd0ZtRm1iMnlGeTk5SmVZTXc0YWxhYnRHSmlYTjk4dHM3WHRKVmFpdFhGanRjT01ycnc5Sk1iWnhvbjBTY2RQdEEwaXBUMzhFbmRKd2tjeWRrSExCbTZwWEtzckl6Vi1mazZNOXFySXFyalFndDhBRzN3Z1drWkNDWW1j?oc=5", "source_name": "GuruFocus", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO\u2122 (tabelecleucel)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdDdCelRHM1A3X0ZkZExVSlUzV1RFaVozM3NkQVRzN0xacGd0VXY2S2RCbUhJbE83SWxtOUh6c1N3bXFfRWZwZ1pWNElkdTRQbEl0bUR6eEc1YjA3dHprVkNFSGtidDRucmpuNTVzSkl4bWM2VUFBa3Nnd0Q4WVdOdENrbDlMd1VlMTJIMnpfQlAwN0xTZ2E4ZFNtZDRUMldzVU16NFBKMGJ6d0ltbjFmNnVsX2VJNGJXdlBNaVpocXpOUXNVT1o2UUFEYmthbXFOTHY4ekhTNnlMOEE?oc=5", "source_name": "Business Wire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Atara's therapy for rare blood cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNYWp5VDE5NTZzRmxwZ1ZYb3RwUXhaRVNnZV9vejRyUHhiRzFZaU8tX214NUtIQlo3TDFZd0VXUUJJcXgtbWJWQjJuVmFXd2FvX0IxNzI3YkpIZzhXTzA4MlF0Tkk0TDIyc1VNZ2hEcFRQYWhLdVFqQTdoZE84X3ZxSERsclFkbFhCSngtaVFZM0lob0hQSHJjYi12UXJHUGJFd0hRaUJJWm45M290WW9vT0R6ZzI1QTlUR1B1SE0xUlV2T255Mkt3?oc=5", "source_name": "Reuters", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNTJiSm55YW40ejlsRm5Cd3I2SDVvZWhqYWt6VE5MVHNEUTZaQ1dQVy1RbXFuM0I3cC14Z2pFVlgwNENHSUJxRlVPT3RMWGRIOE9LMU5NaU5nUTl1ZzN2Y3pKMHVvTmx0cUtZdU91a1RlUHhvakdVNnNibWNVQUJrcmhQV1o1aTZzM2s0S0ctX2o2a2RKVmlJWlZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-30T08:00:00+00:00", "published_display": "30 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 62, "sentiment_summary": {"positive": 7, "negative": 16, "neutral": 39, "score": 45, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.75, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.6, "count": 12}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 16}, "market_context": {"has_market_context": true, "latest_close": 9.76, "latest_week": "2026-07-10", "one_week_move": -16.2, "four_week_move": -6.2, "twelve_week_move": 85.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.839026, "market_dynamics_buy_signal": false, "relative_strength": -19.458044, "fair_value_gap": -31.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.7925, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-16.2% over one week, -6.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "ACCESS Newswire", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Business Wire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 12}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "45/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-16.2% over one week, -6.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of Atara Biotherapeutics Inc \u2013 MUN:AT20"}], "updated_at": "2026-07-16T08:51:00.461723+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}